CN114736917A - Usp11在抑制细胞因子il6降解中的应用 - Google Patents

Usp11在抑制细胞因子il6降解中的应用 Download PDF

Info

Publication number
CN114736917A
CN114736917A CN202210308116.6A CN202210308116A CN114736917A CN 114736917 A CN114736917 A CN 114736917A CN 202210308116 A CN202210308116 A CN 202210308116A CN 114736917 A CN114736917 A CN 114736917A
Authority
CN
China
Prior art keywords
usp11
degradation
cells
cytokine
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210308116.6A
Other languages
English (en)
Other versions
CN114736917B (zh
Inventor
祁小飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou University
Original Assignee
Suzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou University filed Critical Suzhou University
Priority to CN202210308116.6A priority Critical patent/CN114736917B/zh
Publication of CN114736917A publication Critical patent/CN114736917A/zh
Priority to PCT/CN2022/111784 priority patent/WO2023184819A1/zh
Application granted granted Critical
Publication of CN114736917B publication Critical patent/CN114736917B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/19—Omega peptidases (3.4.19)
    • C12Y304/19012—Ubiquitinyl hydrolase 1 (3.4.19.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

IL6是一种重要的细胞因子，在抗感染，肿瘤免疫，免疫细胞发育等过程中发挥着重要的作用，因此维持一定水平的IL6水平，使其免于过早被降解在上述过程中显得非常重要。USP11是参与机体泛素化过程的基因，研究发现其在多种肿瘤中表达异常，未见其参与IL6降解的研究。本发明公开了USP11新的功能‑保护IL6避免降解的作用，为抗感染和肿瘤的治疗提供新的靶点与思路。

Description

USP11在抑制细胞因子IL6降解中的应用
技术领域
本发明属于生物技术，具体公开了USP11在抑制细胞因子IL6 降解中的应用。
背景技术
IL6是一种重要的细胞因子，在抗感染，肿瘤免疫，免疫细胞发育等过程中发挥着重要的作用，因此维持一定的IL6水平，使其免于过早被降解在上述过程中显得非常重要。USP11是参与机体泛素化过程的基因，研究发现其在多种肿瘤中表达异常，未见其参与IL6降解的研究。
发明内容
现有技术针对IL6降解的研究较少，本发明公开了USP11新的功能-保护IL6避免降解的作用，为抗感染和肿瘤的治疗提供新的靶点与思路。
本发明采用如下技术方案：
USP11在抑制细胞因子IL6 降解中的应用。
USP11在制备抑制细胞因子IL6 降解药物中的应用。
过表达USP11的试剂在抑制细胞因子IL6 降解中的应用，或者在制备抑制细胞因子IL6 降解药物中的应用。
本发明中，USP11以病毒载体或者质粒的形式作为药物，比如慢病毒、腺病毒等常规病毒载体。
本发明分别取USP11基因敲除C57小鼠为实验组，对照组为USP11野生型C57小鼠。皮下注射5mg/kg LPS，特定时间点取小鼠血清，ELISA检测IL-6含量，证实USP11能避免IL6过早降解，为抗感染和肿瘤治疗提供更有效的治疗策略及思路。
附图说明
图1为LPS（5mg/kg）处理后小鼠血清内IL-6表达水平。
图2为人重组腺病毒感染293细胞。
图3为Ad-USP11和Ad-NC组细胞IL-6 mRNA表达水平差异。
图4为Ad-USP11和Ad-NC细胞上清液内IL-6表达差异。
图5为慢病毒感染293细胞。
图6为sh-USP11和sh-NC组细胞IL-6 mRNA表达水平差异。
具体实施方式
C57BL/6小鼠(H-2b)为雌性小鼠，周龄为6-8周，体重为17-22 克，购买上海斯莱克实验动物公司。C57BL/6 遗传背景的 USP11-/-小鼠、人293细胞源自苏州大学医学部放射医学与防护学院。小鼠的饮用水、饲料和垫料均经过灭菌处理。所有小鼠均饲养于SPF级别的隔离笼内。所有动物实验均按照苏州大学实验与动物伦理委员要求操作。
Figure 310955DEST_PATH_IMAGE001
超净台消毒灭菌，快速复苏293细胞。用10%血清DMEM培养基（青霉素+链霉素）于无菌培养皿内培养。定期观察。在超净台内用无菌PBS将LPS粉末溶解，配制为1mg/kg的试剂。分装置于-80℃冰箱内待用。
ELSIA检测细胞因子。
血清获得方法。摘眼球取小鼠外周血至于于无热源和内毒素的试管内，室温下静置2h，离心，1000g，30min。取上清液于-80℃待用。
细胞上清液获得方法。观察细胞状态，取细胞融合度约为80%时进行实验。加入胰蛋白酶消化细胞。用预冷的PBS洗涤细胞。加入细胞裂解液（临用前一秒加入蛋白酶抑制剂）进行细胞重悬。离心，4℃ ，10000×g ，10min。取细胞上清，-80℃保存，避免反复冻融。
ELSIA测试。预先进行标号，A1-A6为标准品孔，其他为样品孔，每个样品加3个复孔。按照说明书进行操作，分别加入标准品和样品5ul,样品稀释液45ul。加入酶标抗体100ul,37℃ 30min。洗涤，每次1分钟，洗涤5次。加入显色液A液和B液于37℃孵育15分钟，加入终止液。在酶标仪上于450nm检测各组OD值。
RT-PCR检测mRNA水平。总RNA的获取，小鼠外周血静置2h后进行离心，上层为血清，下层为单核细胞。将上层血清吸取掉后向剩余组织内加入1ml Trizol溶液室温下颠倒混匀15min。加入200ul氯仿，震动1min后静置5min，离心,12000rpm,15min,4℃。将上层吸取至新EP管内，加入500ul异丙醇，冰上30min。离心。弃上清，加1ml 75%乙醇，离心。弃上清液，于通风橱中冰上30min，加入25ul的DEPC水溶解置于-20℃冰箱。RNA浓度的测定，将RNA于-20℃冰箱取出，于震动涡旋器上震荡，吸取2ul的DEPC水做空白对照，其余样品吸取2ul于板上，使用全自动酶标仪进行检测。
本发明具体操作方法以及测试方法为常规技术，GraphPad Prism 8.0作图，SPSS20统计分析。P<0.05定义为有显著性差异。
实施例一
小鼠分组及腹腔注射LPS诱导脓毒血症模型。实验小鼠分组：WT小鼠（USP11野生型）和KO小鼠（USP11基因敲除）各10只，分别接受LPS腹腔注射剂量为5mg/kg。
1.分别取USP11基因敲除C57小鼠为实验组，对照组为USP11野生型C57小鼠，皮下注射5mg/kg LPS。
2. 特定时间点取小鼠血清，行ELISA检测IL-6含量。
3. USP11基因敲除后，小鼠血液中IL-6含量，在LPS刺激4小时后，明显低于未敲除小鼠。说明，USP11有效降低IL-6的降解速度，参见图1。
实施例二
重组腺病毒Ad-USP11转染293细胞。显微镜下观察293细胞细胞融合至70%后，消化细胞，离心。分为实验组（Ad-USP11）和对照组（Nc-USP11）弃掉上清液，向每个孔内一次加入病毒稀释液和细胞培养基，混匀，培养24h后更换正常培养基，观察细胞状态。48h后，胰蛋白酶消化细胞，离心，重悬细胞观察状态，用于后续实验。取上述培养好的细胞，加入LPS（1ug/ml）刺激293细胞产生IL-6。
实施例三
慢病毒sh-USP11转染293细胞。293细胞融合度为70%时，使用胰酶将细胞下滑下来，计数，调整细胞浓度。使用培养基重悬细胞，滴加慢病毒试剂。实验组为（sh-USP11），对照组为（sh-NC）。慢病毒用量：病毒体积=（MOI×细胞数）/病毒滴度。12h后更换为正常培养基，继续培养，观察细胞状态。感染72小时后，qRT-PCR检测感染效率用于后续实验。取上述培养好的细胞，加入LPS（1ug/ml）刺激293细胞产生IL-6。
观测LPS（1ug/ml）处理实施例二及实施例三细胞后IL-6表达水平的变化，在细胞水平验证USP11和IL-6的相关性。使用LPS刺激过表达USP11和对照组的293细胞，测IL-6的表达量。从图2可以看到USP11过表达成功，图3看到高表达USP11组IL-6的mRNA水平较正常对照组增高（P<0.05），同时图4看到ELSIA检测细胞上清液测高表达USP11组的IL-6水平明显高于对照组（P<0.05）。同样的，取293细胞进行慢病毒包装，设置USP11低表达组（sh-USP11）和对照组（sh-NC），从图5可以得出慢病毒下调USP11表达量模型建立成功，图6可以看到下调USP11后IL-6的mRNA表达水平随之下降（P<0.05）。
IL-6 可由多种细胞分泌，其负责协调T细胞扩增和分化，USP11作为一种重要的去泛素化酶，在免疫细胞的活化起着重要作用；脂多糖(LPS)诱导的细胞分泌IL-6等，本发明通过实验公开了USP11新的功能-保护IL6，避免过早降解。

Claims (7)

1.USP11在抑制细胞因子IL6 降解中的应用。
2.USP11在制备抑制细胞因子IL6 降解药物中的应用。
3.根据权利要求2所述的应用，其特征在于，药物为病毒载体药物或者质粒药物。
4.过表达USP11的试剂在抑制细胞因子IL6 降解中的应用。
5.根据权利要求4所述的应用，其特征在于，过表达USP11的试剂为病毒载体试剂或者质粒试剂。
6.过表达USP11的试剂在制备抑制细胞因子IL6 降解药物中的应用。
7.根据权利要求6所述的应用，其特征在于，过表达USP11的试剂为病毒载体试剂或者质粒试剂。
CN202210308116.6A 2022-03-27 2022-03-27 Usp11在抑制细胞因子il6降解中的应用 Active CN114736917B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210308116.6A CN114736917B (zh) 2022-03-27 2022-03-27 Usp11在抑制细胞因子il6降解中的应用
PCT/CN2022/111784 WO2023184819A1 (zh) 2022-03-27 2022-08-11 Usp11 在抑制细胞因子 il6 降解中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210308116.6A CN114736917B (zh) 2022-03-27 2022-03-27 Usp11在抑制细胞因子il6降解中的应用

Publications (2)

Publication Number Publication Date
CN114736917A true CN114736917A (zh) 2022-07-12
CN114736917B CN114736917B (zh) 2023-08-01

Family

ID=82278070

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210308116.6A Active CN114736917B (zh) 2022-03-27 2022-03-27 Usp11在抑制细胞因子il6降解中的应用

Country Status (2)

Country Link
CN (1) CN114736917B (zh)
WO (1) WO2023184819A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023184819A1 (zh) * 2022-03-27 2023-10-05 苏州大学 Usp11 在抑制细胞因子 il6 降解中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037200A2 (en) * 2003-10-09 2005-04-28 Pacific Arrow Limited Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
CN105251020A (zh) * 2015-09-29 2016-01-20 武汉大学 泛素特异性蛋白酶4（usp4）在治疗心肌肥厚中的功能及应用
CN109771648A (zh) * 2019-03-11 2019-05-21 上海市东方医院（同济大学附属东方医院） 去泛素化酶usp11的抑制剂在制备预防或治疗尿酸性肾病药物中的用途
WO2021216460A1 (en) * 2020-04-19 2021-10-28 Figene, Llc Gene modified fibroblasts for therapeutic applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015118338A1 (en) * 2014-02-07 2015-08-13 Mission Therapeutics Limited Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways
US11261466B2 (en) * 2015-03-02 2022-03-01 Sinai Health System Homologous recombination factors
CN114736917B (zh) * 2022-03-27 2023-08-01 苏州大学 Usp11在抑制细胞因子il6降解中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037200A2 (en) * 2003-10-09 2005-04-28 Pacific Arrow Limited Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
CN105251020A (zh) * 2015-09-29 2016-01-20 武汉大学 泛素特异性蛋白酶4（usp4）在治疗心肌肥厚中的功能及应用
CN109771648A (zh) * 2019-03-11 2019-05-21 上海市东方医院（同济大学附属东方医院） 去泛素化酶usp11的抑制剂在制备预防或治疗尿酸性肾病药物中的用途
WO2021216460A1 (en) * 2020-04-19 2021-10-28 Figene, Llc Gene modified fibroblasts for therapeutic applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WENJING SUN等: "USP11 Negatively Regulates TNFα-Induced NF-κB Activation by Targeting on IκBα", 《CELL SIGNAL》, vol. 22, no. 3, pages 7 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023184819A1 (zh) * 2022-03-27 2023-10-05 苏州大学 Usp11 在抑制细胞因子 il6 降解中的应用

Also Published As

Publication number Publication date
CN114736917B (zh) 2023-08-01
WO2023184819A1 (zh) 2023-10-05

Similar Documents

Publication Publication Date Title
JP6890831B2 (ja) Ｈｉｖ予備免疫化および免疫療法
EP2918598B1 (en) Brachyury polypeptides and methods for use
US20070243215A1 (en) Adjuvant for Dna Vaccines
MX2008012392A (es) Mutacion de ras, y composiciones y metodos relacionados con la misma.
CN114736917A (zh) Usp11在抑制细胞因子il6降解中的应用
US20230181645A1 (en) Method to improve cancer vaccines
CN110157686B (zh) 一种免疫检查点激活免疫共刺激的复制型溶瘤腺病毒及其构建方法和应用
EP2386633A1 (en) Novel cancer antigen eef2
KR100795839B1 (ko) 세균의 편모 구성인자 플라젤린을 유효성분으로 함유하는점막 백신 보조제
US20230256072A1 (en) Compositions and methods for vaccination against neisseria gonorrhoeae
US8183220B2 (en) Double-effective vaccine vector against foot-and-mouth disease virus (FMDV), methods of preparing and using the same
CN112675308B (zh) 抑制enpp2基因和/或蛋白表达的物质在制备治疗多发性骨髓瘤的药物中的应用
EP2411035A1 (en) Oncofetal antigen/immature laminin receptor peptides for the sensitization of dendritic cells for cancer therapy
CN111803646A (zh) 一种实体肿瘤联合治疗组合物
CN110804088A (zh) 巨细胞病毒相关抗原短肽及其应用
KR20190135296A (ko) 돼지생식기호흡기증후군 바이러스 Ｎｓｐ１ 단백질을 유효성분으로 포함하는 면역증강용 조성물
US9315558B2 (en) Use of interleukin 10 mRNA transfected macrophages in anti-inflammatory therapies
CN113185586B (zh) SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用
WO2023155236A1 (zh) 一种EBNA3A截短mRNA相关疫苗及其制备方法和应用
CN117904054A (zh) 新冠病毒SARS-CoV-2特异性T细胞及其应用
CN118086212A (zh) 新冠病毒表位多肽致敏的树突状细胞及其应用
WO2021252604A1 (en) Coronavirus disease 2019 (covid-19) combination vaccine
CN113930438A (zh) 一种重组的耻垢分枝杆菌、疫苗及其应用
CN116688128A (zh) 微肽altTAP2在制备抗骨髓瘤药物中的应用
CN110818787A (zh) 一种增加Ly6C+巨噬细胞的抗原及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant